Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/s0248-8663(89)80053-0 | DOI Listing |
Blood Adv
January 2025
Ente Ospedaliero Cantonale, Switzerland.
The Swiss Group for Clinical Cancer Research (SAKK) and the Nordic Lymphoma Group (NLG) conducted the SAKK 35/10 randomized phase-2 trial (NCT0137605) to compare rituximab (R) alone versus R plus lenalidomide (L) as initial treatment for follicular lymphoma (FL). Patients with grade 1-3a FL, requiring systemic therapy, were randomized to either R (n=77; 375 mg/m2 IV x 1, weeks 1-4) or RL (n=77; R on the same schedule and L at 15 mg daily continuously). Responders (evaluated at 10 weeks) repeated R during weeks 12-15 with or without L (for a total of 18 weeks).
View Article and Find Full Text PDFJ Cutan Med Surg
January 2025
Division of Dermatology, Jewish General Hospital/Lady Davis Institute for Medical Research, McGill University, Montreal, QC, Canada.
Nat Commun
January 2025
Department of Biomedicine, Translational Immuno-Oncology, University and University Hospital Basel, Basel, Switzerland.
Nat Commun
January 2025
Research Division, Autolus Therapeutics, London, UK.
Clin Genitourin Cancer
January 2025
Department of Pathology, The First Medical Centre, Chinese PLA General Hospital, Beijing, China. Electronic address:
Objective: To investigate the clinical characteristics, pathology, imaging features, and prognosis of primary renal lymphoma (PRL), a rare malignancy.
Patients And Method: We conducted a retrospective review of 14 PRL cases diagnosed between January 2009 and January 2022, with follow-up data collected from medical records.
Results: The study included 14 patients (7 males, 7 females), with a mean age of 60.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!